Skip to content
ETEN
Findshops
Science & Health

Large Survey: People with Eating Disorders Rated Perceived Benefits of Cannabis and Psychedelics Highly

Illustrative photograph accompanying an eating disorders survey article

A large international survey published in 2025 added a striking finding to the debate about cannabis’s therapeutic potential: respondents with eating disorders rated cannabis, psilocybin and LSD most positively for their perceived relief of eating disorder symptoms. Cannabis was also the substance most frequently selected for self-directed symptom relief.

The study was published on 22 July 2025 in JAMA Network Open. Its results do not establish the clinical effectiveness of these substances. Our article on THC’s effects on appetite explores the relationship between cannabis and appetite in more detail.

More than 7,600 respondents: what did the survey ask?

Illustrative photograph, not a participant in the eating disorders survey
Illustrative photo: Evan Strock / Unsplash. The photograph does not show survey participants.

The international MED-FED study, led by University of Sydney researchers, initially involved 7,648 people who reported an eating disorder or disordered eating. Of these, 6,612 completed the demographic section and 5,123 completed the entire questionnaire. This was an online survey, rather than a clinical drug trial: people described prescription and nonprescription substance use and the benefits and harms they perceived.

Respondents assessed whether different substances helped their eating disorder symptoms and general mental health, and reported perceived adverse effects. Conditions covered included anorexia nervosa, bulimia nervosa, binge eating disorder and avoidant/restrictive food intake disorder (ARFID).

Cannabis and psilocybin stood out

For perceived relief of eating disorder symptoms, cannabis and psilocybin shared the highest average rating (+0.50 on the study’s scale), followed by LSD (+0.33). Cannabis had been used in the preceding year by 3,018 respondents, of whom 42.1% reported daily use. These figures show that cannabis played a substantial role in the experiences of the people surveyed.

Cannabis was named most frequently when respondents were asked which substance they preferred for self-directed symptom relief. When preferences were considered relative to the number of users of each substance, however, the prescription medicine fluoxetine ranked first. The results therefore support more than one perspective, while clearly showing high perceived benefit ratings for cannabis.

Why does this deserve attention?

Eating disorders can affect appetite, mood, body perception and everyday life. Cannabis-related research questions include changes in appetite, anxiety and pleasure, but these mechanisms alone cannot tell us which patients might benefit from a particular cannabinoid medicine.

An important contribution of the study is that it highlights patients’ own experiences. When many respondents perceive relief from substances that have not been adequately studied as eating disorder treatments, those experiences deserve scientific attention rather than automatic dismissal.

What do the results not show?

People chose whether to take part and assessed substance effects themselves. The results therefore cannot establish whether cannabis or psychedelics would outperform standard treatments in a controlled clinical trial. Different eating disorders also involve different risks, and stimulating appetite may not be appropriate for everyone.

The possible medical uses of cannabis and psychedelics merit open discussion, but people with eating disorders need professional support. This survey does not justify recommending these substances as self-administered treatments.

What comes next?

The researchers concluded that the potential benefits of cannabis and psychedelics warrant further investigation. This offers a positive direction for cannabis research: patients’ experiences may help identify research questions and gaps in care that the current system does not always recognise.

Original source: Rodan et al., ‘Prescription and Nonprescription Drug Use Among People With Eating Disorders’, JAMA Network Open (2025), DOI 10.1001/jamanetworkopen.2025.22406.

Sources

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *